Chirag G. Patel

Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Saxagliptin

David W. Boulton, Li Li, Ernst U. Frevert et al. · Clinical Pharmacokinetics · 2011 · 108 citations

Pharmacy, Pharmacokinetics, Pharmacology +12

<scp>TAK</scp>‐228 (formerly <scp>MLN</scp>0128), an investigational oral dual <scp>TORC</scp>1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non‐Hodgkin lymphoma, or Waldenström's macroglobulinemia

Irene M. Ghobrial, David S. Siegel, Ravi Vij et al. · American Journal of Hematology · 2016 · 94 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

High-Performance Liquid Chromatography Method for the Determination of Mycophenolic Acid and Its Acyl and Phenol Glucuronide Metabolites in Human Plasma

Chirag G. Patel, Fatemeh Akhlaghi · Therapeutic Drug Monitoring · 2006 · 45 citations · Full text

Pharmacy, Pharmaceutical Analysis, Pharmacology +17

TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies

Howard A. Burris, Carla Kurkjian, L. Hart et al. · Cancer Chemotherapy and Pharmacology · 2017 · 45 citations

Medicine, Oncology, Pharmacology +8

Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase‐4 inhibitor, in healthy subjects

Vijay Upreti, David W. Boulton, Li Li et al. · British Journal of Clinical Pharmacology · 2011 · 30 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +16